Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease

European Journal of Pharmacology

Volumn 393, Issue 1-3, 2000, Pages 165-170

  Maelicke, Alfred ^a   Albuquerque, Edson X ^b  

^a Inst Physiologische Chem P   (Germany)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Allosteric modulation; Alzheimer's disease; Cholinergic deficit; Galanthamine; Nicotinic acetylcholine receptor

Indexed keywords

1 METHYLGALANTAMINE; ACETYLCHOLINE; ALKALOID; CODEINE; GALANTAMINE; NICOTINIC RECEPTOR; PHYSOSTIGMINE; SEROTONIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ANIMAL CELL; CHANNEL GATING; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SENSITIZATION;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; ANIMALS; CELLS, CULTURED; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION; GALANTAMINE; HUMANS; LEARNING; NEUROTRANSMITTER AGENTS; PC12 CELLS; RATS; RECEPTORS, NICOTINIC;

EID: 0034732104     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00093-5     Document Type: Conference Paper

References (42)

1. Akaike A., Tamura Y., Yokota T., Shimohama S., Kimura J. Nicotinie-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
2. Albuquerque E.X., Alkondon M., Pereira E.F., Castro N., Schrattenholz A., Barbosa C., Bonfante-Cabarcas R., Aracava Y., Eisenberg H., Maelicke A. Properties of neuronal nicotinic acetylcholine receptors, pharmacological characterization and modulation of synaptic function. J. Pharmacol. Exp. Ther. 280:1996;1117-1136.
3. Albuquerque E.X., Pereira E.F.R., Bonfante-Cabarcas R., Marchioro M., Matsubayashi H., Alkondon M., Maelicke A. Nicotinic acetylcholine receptors on hippocampal neurons: cell compartment-specific expression and modulatory control of channel activity. Prog. Brain Res. 109:1996;111-124.
4. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors. Eur. J. Neurosci. 9:1997;2734-2742.
5. Alkondon M., Pereira E.F.R., Eisenberg H., Albuquerque E.X. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J. Neurosci. 1999;. in press.
6. Alkondon M., Pereira E.F.R., Eisenberg H.M., Albuquerque E.X. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J. Neurosci. 19:1999;2693-2705.
7. Bjugstad K., Mahnir V., Klein W., Socci D., Arendash G. Long term treatment with GTS-21 or nicotine enhances water maze performance in aged rates without affecting the density of nicotinic receptor subtypes in neocortex. Drug Dev. Res. 39:1996;19-28.
8. Castro N.G., Albuquerque E.X. α-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys. J. 68:1995;516-524.
9. Court J.A., Perry E.K. CNS nicotine receptors. Possible therapeutic targets in neurodegenerative disorders. CNS Drugs. 2:1994;216-233.
10. Descarries L. The hypothesis of an ambient level of acetylcholine in the central nervous system. J. Physiol. 92:1998;215-220.
11. Feldman H., Gracon S. Alzheimer's disease: symptomatic drugs under development. Gauthier S. Clinical Diagnosis and Management of Alzheimer's Disease. 1996;Martin Dunitz, London.
12. Flicker L. Acetylcholinesterase inhibitors for Alzheimer's disease. Brit. Med. J. 318:1999;615-616.
13. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol., Neurosurg. Psychiatry. 66:1999;137-147.
14. Freedman R., Coon H., Mylesworsley M., Orr-Utreger A., Olincy A., Davis A. Linkage of neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA. 94:1997;587-592.
15. Hsu Y., Amin J., Weiss D., Wecker L. Sustained nicotine exposure differentially affects α3β2 and α4β2 neuronal nicotinic receptors expressed in Xenopus oocytes. J. Neurochem. 66:1996;667-675.
16. Jürss R., Prinz H., Maelicke A. NBD-5-acylcholine: fluorescent analog of acetylcholine and agonist at the neuromuscular junction. Proc. Natl. Acad. Sci. USA. 76:1979;1064-1068.
17. Katz B., Miledi R. A reexamination of curare action at the motor endplate. Proc. R. Soc. London, Ser. B. 196:1977;59-72.
18. Kihara T., Shimohama S., Urushitani M., Sawanda H., Kimura J., Kume T., Maeda T., Akaike A. Stimulation of α4β2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 792:1998;331-334.
19. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles, Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 22:1996;431-445.
20. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berlin). 138:1998;217-230.
21. Maelicke A. Biochemical aspects of cholinergic excitation. Angew. Chem., Int. Ed. 23:1984;195-221.
22. Maelicke A., Albuquerque E.X. New approach to drug therapy of Alzheimer's dementia. Drugs Dis. Today. 1:1996;53-59.
23. Maelicke A., Schrattenholz A., Schröder H. Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system. Semin. Neurosci. 7:1995;103-114.
24. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., Tsouloufis T., Tzartos S., Ballard C., Perry R.H., Perry E.K. α4 But not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J. Neurochem. 73:1999;1635-1640.
25. McDonald R.L., Twyman R.E. Kinetic properties and regulation of GABA receptor channels. Ion Channels. 3:1992;315-343.
26. Menzaghi F., Whelan K., Risbrough V., Rao T., Lloyd G. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J. Pharmacol. Exp. Ther. 280:1997;384-392.
27. Nordberg A., Lundqvist A., Hartvig P., Lidja A., Langibom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains: in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9:1995;21-27.
28. Nordberg A., Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 19:1998;465-480.
29. 3H) acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:1986;115-119.
30. Pereira E.F.R., Alkondon M., Reinhardt S., Maelicke A., Peng X., Lindstrom J., Whiting P., Albuquerque E.X. Physostigmine and galanthamine: probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J. Pharmacol. Exp. Ther. 270:1994;768-778.
31. Pereira E.F.R., Alkondon M., Tano T., Castro N.G., Froes-Ferrao M.M., Rosental R., Aronstam R.S., Albuquerque E.X. A novel agonist binding site on nicotinic acetylcholine receptors. J. Recept. Res. 13:1993;413-436.
32. Pereira E.F.R., Reinhardt-Maelicke S., Schrattenholz A., Maelicke A., Albuquerque E.X. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 265:1993;1474-1491.
33. Perry E., Morris C., Court J., Cheng A., Fairbairn A., McKeith I., Irving D., Brown A., Perry R. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease, possible index of early neuropathology. Neuroscience. 64:1995;385-395.
34. Potter A., Corwin J., Lang J., Piasecki M., Lenox R., Newhouse P.A. Acute effects of the selective cholinergic channel activator (nicotinic receptor agonist) ABT-418 in Alzheimer's disease. Psychopharmacology. 142:1999;334-342.
35. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
36. Sabey K., Paradiso K., Zhang J., Steinbach J.H. Ligand binding and activation of rat nicotinic α4β2 receptors stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 55:1999;58-66.
37. Schrattenholz A., Pereira E.F.R., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49:1996;1-6.
38. Schröder H., Giacobini E., Strubble R.G., Zilles K., Maelicke A. Nicotinic cholinoreceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol. Aging. 12:1991;259-262.
39. Shaw K.P., Aracava Y., Akaike A., Daly J.W., Rickett D.L., Albuquerque E.X. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol. Pharmacol. 28:1985;527-538.
40. Wevers A., Monteggia L., Lowack S., Bloch W., Schütz U., Lindstrom J., Pereira E.F.R., Arneric S., Sullivan J., Eisenberg H., Giacobini E., Gass P., deVos R.A.I., Jansen S.E.N.H., Maelicke A., Albuquerque E.X., Schröder H. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease - histotopographical correlation with amyloid plaques and hyperphosphorylated τ-protein. Eur. J. Neurosci. 11:1999;2551-2555.
41. Whitehouse P.J., Martino A.M., Antuono P.G.et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1:1986;55-65.
42. Zwart R., Vijverberg H.P.M. Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol. Pharmacol. 52:1997;886-895.